View Item 

Show simple item record

Predictors of multidomain decline in health‐related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer
dc.contributor.authorDess, Robert T.
dc.contributor.authorJackson, William C.
dc.contributor.authorSuy, Simeng
dc.contributor.authorSoni, Payal D.
dc.contributor.authorLee, Jae Y.
dc.contributor.authorAbugharib, Ahmed E.
dc.contributor.authorZumsteg, Zachary S.
dc.contributor.authorFeng, Felix Y.
dc.contributor.authorHamstra, Daniel A.
dc.contributor.authorCollins, Sean P.
dc.contributor.authorSpratt, Daniel E.
dc.date.accessioned2017-05-10T17:47:52Z
dc.date.available2018-07-09T17:42:24Zen
dc.date.issued2017-05-01
dc.identifier.citationDess, Robert T.; Jackson, William C.; Suy, Simeng; Soni, Payal D.; Lee, Jae Y.; Abugharib, Ahmed E.; Zumsteg, Zachary S.; Feng, Felix Y.; Hamstra, Daniel A.; Collins, Sean P.; Spratt, Daniel E. (2017). "Predictors of multidomain decline in health‐related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer." Cancer 123(9): 1635-1642.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/136687
dc.publisherWiley Periodicals, Inc.
dc.subject.otherExpanded Prostate Cancer Index (EPIC)
dc.subject.otherhealth‐related quality of life (HRQOL)
dc.subject.otherPatient‐reported outcomes (PRO)
dc.subject.otherprostate cancer
dc.subject.otherstereotactic body radiation (SBRT)
dc.titlePredictors of multidomain decline in health‐related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136687/1/cncr30519_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136687/2/cncr30519.pdf
dc.identifier.doi10.1002/cncr.30519
dc.identifier.sourceCancer
dc.identifier.citedreferenceDonovan JL, Hamdy FC, Lane JA, et al. Patient‐reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016; 375: 1425 ‐ 1437.
dc.identifier.citedreferenceHannan R, Tumati V, Xie XJ, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer—results from a multi‐institutional clinical trial. Eur J Cancer. 2016; 59: 142 ‐ 151.
dc.identifier.citedreferenceInstitute of Clinical Research‐Clinical Trials and Statistics Unit, Division of Clinical Studies. The Prostate Advances in Comparative Evidence (PACE) Study: International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventionally fractionated radiotherapy vs SBRT for early stage organ‐confined prostate cancer. Available at: http://www.isrctn.com/ISRCTN17627211. Accessed October 11, 2016.
dc.identifier.citedreferenceWidmark A. Phase III study of hypofractionated radiotherapy of intermediate risk localized prostate cancer. Available at: http://www.isrctn.com/ISRCTN45905321. Accessed October 11, 2016.
dc.identifier.citedreferenceHalpern JA, Sedrakyan A, Hsu WC, et al. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer. Cancer. 2016; 122: 2496 ‐ 2504.
dc.identifier.citedreferenceBaker BR, Basak R, Mohiuddin JJ, Chen RC. Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012. Cancer. 2016; 122: 2234 ‐ 2241.
dc.identifier.citedreferenceYu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic body radiation therapy versus intensity‐modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol. 2014; 32: 1195 ‐ 1201.
dc.identifier.citedreferenceD’Amico AV. Stereotactic body radiation therapy versus intensity‐modulated radiation therapy for prostate cancer: less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis. J Clin Oncol. 2014; 32: 1183 ‐ 1185.
dc.identifier.citedreferenceSzymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the Expanded Prostate Cancer Index Composite instrument for measuring health‐related quality of life among prostate cancer survivors. Urology. 2010; 76: 1245 ‐ 1250.
dc.identifier.citedreferenceKing CR, Collins S, Fuller D, et al. Health‐related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi‐institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys. 2013; 87: 939 ‐ 945.
dc.identifier.citedreferenceCleeland CS. Symptom burden: multiple symptoms and their impact as patient‐reported outcomes. J Natl Cancer Inst Monogr. 2007; 37: 16 ‐ 21.
dc.identifier.citedreferenceChen LN, Suy S, Uhm S, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience [serial online]. Radiat Oncol. 2013; 8: 58.
dc.identifier.citedreferenceMercado C, Kress MA, Cyr RA, et al. Intensity‐modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: the Georgetown University experience [serial online]. Front Oncol. 2016; 6: 114.
dc.identifier.citedreferenceJaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989; 10: 407 ‐ 415.
dc.identifier.citedreferenceSkolarus TA, Dunn RL, Sanda MG, et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015; 85: 101 ‐ 106.
dc.identifier.citedreferenceCharlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373 ‐ 383.
dc.identifier.citedreferenceZumsteg ZS, Spratt DE, Pei I, et al. A new risk classification system for therapeutic decision making with intermediate‐risk prostate cancer patients undergoing dose‐escalated external‐beam radiation therapy. Eur Urol. 2013; 64: 895 ‐ 902.
dc.identifier.citedreferenceChen RC, Chang P, Vetter RJ, et al. Recommended patient‐reported core set of symptoms to measure in prostate cancer treatment trials [serial online]. J Natl Cancer Inst. 2014; 106: dju132.
dc.identifier.citedreferenceSanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate‐cancer survivors. N Engl J Med. 2008; 358: 1250 ‐ 1261.
dc.identifier.citedreferenceResnick MJ, Koyama T, Fan KH, et al. Long‐term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013; 368: 436 ‐ 445.
dc.identifier.citedreferenceKing CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi‐institutional consortium of prospective phase II trials. Radiother Oncol. 2013; 109: 217 ‐ 221.
dc.identifier.citedreferenceEvans JR, Zhao S, Daignault S, et al. Patient‐reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015; 116: 179 ‐ 184.
dc.identifier.citedreferenceBorghede G, Hedelin H. Radiotherapy of localised prostate cancer. Analysis of late treatment complications. A prospective study. Radiother Oncol. 1997; 43: 139 ‐ 146.
dc.identifier.citedreferenceSmit WG, Helle PA, van Putten WL, Wijnmaalen AJ, Seldenrath JJ, van der Werf‐Messing BH. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990; 18: 23 ‐ 29.
dc.identifier.citedreferenceWhitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002; 122: 1140 ‐ 1156.
dc.identifier.citedreferenceMohamed NE, Bovbjerg DH, Montgomery GH, Hall SJ, Diefenbach MA. Pretreatment depressive symptoms and treatment modality predict post‐treatment disease‐specific quality of life among patients with localized prostate cancer. Urol Oncol. 2012; 30: 804 ‐ 812.
dc.identifier.citedreferenceMiller DC, Sanda MG, Dunn RL, et al. Long‐term outcomes among localized prostate cancer survivors: health‐related quality‐of‐life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005; 23: 2772 ‐ 2780.
dc.identifier.citedreferenceZaorsky NG, Egleston BL, Horwitz EM, et al. The missing pieces in reporting of randomized controlled trials of external beam radiation therapy dose escalation for prostate cancer. Am J Clin Oncol. 2016; 39: 321 ‐ 326.
dc.identifier.citedreferenceQi X, Wang J, Gomez CL, et al. Patient‐reported outcome after prostate stereotactic body radiation therapy—an analysis of dosimetric correlation of minimally import difference for the Expanded Prostate Cancer Index Composite Short Form (EIPIC‐26) [abstract]. Int J Radiat Oncol Biol Phys. 2016; 96 ( suppl ): E227.
dc.identifier.citedreferenceKing CR, Brooks JD, Gill H, Presti JC Jr. Long‐term outcomes from a prospective trial of stereotactic body radiotherapy for low‐risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82: 877 ‐ 882.
dc.identifier.citedreferenceFuller DB, Naitoh J, Mardirossian G. Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5‐year disease‐free survival and toxicity observations [serial online]. Front Oncol. 2014; 4: 321.
dc.identifier.citedreferenceKatz A, Kang J. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high‐risk prostate carcinoma: a 6 year study [serial online]. Radiat Oncol. 2014; 9: 1.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr30519_am.pdf
Size:
1.256MB
Format:
PDF
View/Open
Name:
cncr30519.pdf
Size:
396.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.